Skip to main content
Clinical Trials/ISRCTN26119679
ISRCTN26119679
Completed
未知

A double blind randomised controlled trial of post-operative low molecular weight heparin bridging therapy versus placebo bridging therapy for patients who are at high risk for arterial thromboembolism

ondon Health Sciences Centre (Canada)0 sites1,773 target enrollmentJune 4, 2008

Overview

Phase
未知
Intervention
Not specified
Conditions
Arterial thromboembolism
Sponsor
ondon Health Sciences Centre (Canada)
Enrollment
1773
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Registry
who.int
Start Date
June 4, 2008
End Date
May 1, 2011
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ondon Health Sciences Centre (Canada)

Eligibility Criteria

Inclusion Criteria

  • 1\. Informed consent
  • 2\. Patients of either sex, 18 years and older, with prosthetic heart valves receiving long\-term oral anticoagulation with warfarin, or
  • 3\. Patients with atrial fibrillation and a major risk factor (previous transient ischaemic attack (TIA) or stroke, high blood pressure, diabetes, 75 years and older, moderate/severe left ventricle dysfunction), who require elective non\-cardiac surgery or an invasive procedure with reversal of their anticoagulant therapy

Exclusion Criteria

  • 1\. Evidence of active bleeding prior to stopping warfarin
  • 2\. Platelet count less than 100 x 10^9/L
  • 3\. Spinal or neurosurgery
  • 4\. Life expectancy less than three months
  • 5\. Serum creatinine greater than 150 umol/L
  • 6\. Patients requiring cardiac surgery
  • 7\. Multiple prosthetic valves or Starr\-Edwards valves or prosthetic valves with a history of stroke or TIA

Outcomes

Primary Outcomes

Not specified

Similar Trials